Parkinson's Disease Explained: Dopamine, Neurons, and Treatment

By the Time Tremors Begin, 60–80% of the Relevant Neurons Are Already Gone

Parkinson's disease is diagnosed when patients and doctors notice its hallmark motor symptoms — the characteristic tremor at rest, the slowing of movement, the rigid muscles. At that point, imaging and post-mortem studies tell us that 60–80% of the dopamine-producing neurons in a specific brain region (the substantia nigra pars compacta) have already been lost. The disease's neurological damage precedes its clinical recognition by years, possibly decades — a timeline that simultaneously explains the difficulty of early diagnosis and the challenge of intervention before irreversible loss occurs.

The Pathological Process: Alpha-Synuclein and Lewy Bodies

At the cellular level, Parkinson's disease is characterized by the abnormal accumulation of a protein called alpha-synuclein inside neurons. In healthy neurons, alpha-synuclein is a normal protein involved in synaptic function. In Parkinson's disease, it misfolds and aggregates into fibrous clumps that accumulate in structures called Lewy bodies and Lewy neurites — microscopic protein aggregates visible in post-mortem brain tissue.

The precise mechanism by which alpha-synuclein aggregation causes neuronal death is not fully established. Leading hypotheses include:

• Impaired protein degradation systems (ubiquitin-proteasome system and autophagy) that can no longer clear misfolded protein
• Mitochondrial dysfunction — alpha-synuclein aggregates impair mitochondrial function and increase oxidative stress
• Neuroinflammation — aggregates trigger microglial activation and inflammatory cascades that kill neurons
• Prion-like propagation — misfolded alpha-synuclein may spread from neuron to neuron through synaptic connections, explaining the progressive spread of pathology through the brain over time

The prion-like propagation hypothesis, supported by the Braak staging system, suggests Parkinson's pathology begins in the brainstem and peripheral nervous system decades before it reaches the substantia nigra — potentially explaining why constipation, REM sleep behavior disorder, and reduced sense of smell precede motor symptoms by years.

The Dopamine Deficit and Motor Symptoms

The substantia nigra is part of the basal ganglia — a circuit of brain structures involved in initiating and modulating voluntary movement. Dopaminergic neurons from the substantia nigra project to the striatum (a key basal ganglia structure), where dopamine release facilitates the initiation and smoothing of movement. When dopamine falls below approximately 20–30% of normal levels, the basal ganglia circuit becomes dysregulated, producing the cardinal motor features of Parkinson's disease:

Non-Motor Symptoms: The Overlooked Burden

Parkinson's disease extends well beyond motor dysfunction. Non-motor symptoms often appear before motor symptoms and can be as disabling as the movement problems:

• Cognitive changes: Mild cognitive impairment affects 20–50% of patients; Parkinson's disease dementia develops in 50–80% over time
• Depression and anxiety: Affect 40–50% of patients; partly driven by dopamine deficiency and partly by non-dopaminergic pathology
• REM sleep behavior disorder (RBD): Physically acting out dreams during REM sleep; precedes motor symptoms in many patients by 10–15 years
• Autonomic dysfunction: Orthostatic hypotension (dizziness on standing), constipation, urinary problems, excessive sweating
• Anosmia: Loss of smell — one of the earliest and most consistent prodromal symptoms, present in ~95% of Parkinson's patients
• Psychosis and hallucinations: Visual hallucinations occur in 20–40% of patients, often related to medication side effects or disease progression

Treatment: Managing Dopamine Deficit

No treatment currently slows or stops Parkinson's disease progression. Available therapies address symptoms by compensating for the dopamine deficit:

Research Directions: Neuroprotection and Beyond

The critical unmet need in Parkinson's research is a disease-modifying therapy — something that slows neurodegeneration rather than just compensating for it. Active areas include:

• Alpha-synuclein targeting: Immunotherapy approaches using antibodies against alpha-synuclein aggregates; antisense oligonucleotides to reduce alpha-synuclein production
• GBA1 gene therapies: Mutations in GBA1 (the glucocerebrosidase gene) are the most common genetic risk factor for Parkinson's; gene therapy and enzyme replacement approaches are in clinical trials
• LRRK2 inhibitors: LRRK2 mutations cause autosomal dominant Parkinson's; kinase inhibitors targeting LRRK2 are in Phase 2 trials
• Focused ultrasound: Non-invasive alternative to DBS for tremor in carefully selected patients; FDA approved since 2016

Parkinson's disease affects approximately 10 million people globally and 1 million in the US, with incidence increasing as populations age. It is the fastest-growing neurological disorder in the world by age-adjusted incidence — a trajectory that makes the search for disease-modifying therapies increasingly urgent.

This article is for informational purposes only. Consult a qualified healthcare professional for medical advice regarding any health condition.